Cambridge, MA Drug Co Biogen Reported a 4Q 2017 Net Loss of $166 Mil, Down $814 Mil From Its Net Income of $648 Mil in the 4Q 2016 ..................................................................................... 144% of the 4Q 2017 Net Income Decline of $814 Mil Was Due To the Impact of the Trump Tax Bill, Which Reduced Biogen's 4Q 2017 Earnings By $1,174 Mil, $990 Mil of Which is the Transition Toll Tax ...................................................................................... It's Not Just Biogen, the Trump Tax Bill is Very Unfriendly Initially to Many Multi-National Drug Companies